Octreotide and Octreotide-derived delivery systems

J Drug Target. 2023 Jul;31(6):569-584. doi: 10.1080/1061186X.2023.2216895. Epub 2023 May 23.

Abstract

Pharmaceutical peptide Octreotide is a somatostatin analog with targeting and therapeutic abilities. Over the last decades, Octreotide has been developed and approved to treat acromegaly and neuroendocrine tumours, and Octreotide-based radioactive conjugates have been leveraged clinically to detect small neuroendocrine tumour sites. Meanwhile, variety of Octreotide-derived delivery strategies have been proposed and explored for tumour targeted therapeutics or diagnostics in preclinical or clinical settings. In this review, we especially focus on the preclinical development and applications of Octreotide-derived drug delivery systems, diagnostic nanosystems, therapeutic nanosystems and multifunctional nanosystems, we also briefly discuss challenges and prospects of these Octreotide-derived delivery systems.

Keywords: Octreotide; cancer therapy; diagnostic nanosystems; drug delivery; therapeutic nanosystems; tumour targeting.

Publication types

  • Review